Physician profile
Jay E Rissover
NPI 1639140890
$10,969.53
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,901 · 2020: $1,036 · 2021: $2,150 · 2022: $2,550 · 2023: $2,192 · 2024: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,332.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,640.72 | 2019-2023 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,269.65 | 2019-2023 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $973.98 | 2019-2022 | |
| Novo Nordisk INC | $863.57 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $823.00 | 2019-2023 | Vraylar, Ubrelvy, Qulipta |
| Abbott Laboratories | $730.60 | 2021-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $670.34 | 2019-2023 | Mounjaro, Jardiance |
| Pfizer INC. | $496.19 | 2019-2023 | |
| Glaxosmithkline, LLC. | $439.12 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $355.20 | 2019-2023 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company Ltd. | $322.32 | 2022 | |
| Dexcom, INC. | $223.08 | 2022-2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $198.86 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $158.60 | 2019-2023 | Belsomra, Steglatro |
| Amarin Pharma, INC. | $150.83 | 2019-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Rissover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.